NO144773B - ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINES - Google Patents
ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINES Download PDFInfo
- Publication number
- NO144773B NO144773B NO752765A NO752765A NO144773B NO 144773 B NO144773 B NO 144773B NO 752765 A NO752765 A NO 752765A NO 752765 A NO752765 A NO 752765A NO 144773 B NO144773 B NO 144773B
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compound
- above meaning
- residue
- acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 16
- 150000001412 amines Chemical class 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title description 7
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 239000002585 base Substances 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- QXSAKPUBHTZHKW-UHFFFAOYSA-N 4-hydroxybenzamide Chemical compound NC(=O)C1=CC=C(O)C=C1 QXSAKPUBHTZHKW-UHFFFAOYSA-N 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000003700 epoxy group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 16
- 229940109275 cyclamate Drugs 0.000 description 15
- 239000002253 acid Substances 0.000 description 13
- -1 hydroxy- Chemical class 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000155 melt Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- MHIAMONBYDFGFO-UHFFFAOYSA-N 4-(2-aminoethoxy)benzamide Chemical compound NCCOC1=CC=C(C(N)=O)C=C1 MHIAMONBYDFGFO-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 125000001589 carboacyl group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229940031826 phenolate Drugs 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- SKQDKFOTIPJUSV-UHFFFAOYSA-N 4-[2-[[2-hydroxy-3-(2-methylphenoxy)propyl]amino]ethoxy]benzamide Chemical compound CC1=CC=CC=C1OCC(O)CNCCOC1=CC=C(C(N)=O)C=C1 SKQDKFOTIPJUSV-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 2
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 230000003454 betamimetic effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052987 metal hydride Inorganic materials 0.000 description 2
- 150000004681 metal hydrides Chemical class 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- DURULFYMVIFBIR-UHFFFAOYSA-N practolol Chemical compound CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1 DURULFYMVIFBIR-UHFFFAOYSA-N 0.000 description 2
- 229960001749 practolol Drugs 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
- 229960003147 reserpine Drugs 0.000 description 2
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003797 solvolysis reaction Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 2
- 229950003004 tolamolol Drugs 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- HUSXNIFVQFHSEA-UHFFFAOYSA-N 2-hydroxypropanoic acid;hydrochloride Chemical compound Cl.CC(O)C(O)=O HUSXNIFVQFHSEA-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- BMTAFVWTTFSTOG-UHFFFAOYSA-N Butylate Chemical compound CCSC(=O)N(CC(C)C)CC(C)C BMTAFVWTTFSTOG-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100459292 Mus musculus Myl1 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- GHVZOJONCUEWAV-UHFFFAOYSA-N [K].CCO Chemical compound [K].CCO GHVZOJONCUEWAV-UHFFFAOYSA-N 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000005915 ammonolysis reaction Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N beta-hydroxyethanesulfonic acid Natural products OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- LZCOQTDXKCNBEE-IKIFYQGPSA-N methscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 description 1
- AGJSNMGHAVDLRQ-IWFBPKFRSA-N methyl (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-IWFBPKFRSA-N 0.000 description 1
- 229960001383 methylscopolamine Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- IHYNKGRWCDKNEG-UHFFFAOYSA-N n-(4-bromophenyl)-2,6-dihydroxybenzamide Chemical compound OC1=CC=CC(O)=C1C(=O)NC1=CC=C(Br)C=C1 IHYNKGRWCDKNEG-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000002746 orthostatic effect Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- NESLWCLHZZISNB-UHFFFAOYSA-M sodium phenolate Chemical compound [Na+].[O-]C1=CC=CC=C1 NESLWCLHZZISNB-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Description
Oppfinnelsen vedrører en analogifremgangsmåte The invention relates to an analogy method
for fremstilling av aminer med fl-reseptor-blokkerende aktivitet og som er anvendelige i behandling av kardio- for the production of amines with fl-receptor-blocking activity and which are applicable in the treatment of cardio-
vaskulære sykdommer og som har den generelle formel I vascular diseases and which have the general formula I
hvori R<1> i 2-stilling er HOC2H4NHCOCH20- eller CH3<OC>2<H>4<->wherein R<1> in the 2-position is HOC2H4NHCOCH20- or CH3<OC>2<H>4<->
NHCOCH20-, NHCOCH20-,
eller terapeutisk tålbare salter herav. or therapeutically tolerable salts thereof.
De nye forbindelser har verdifulle farmakolo- The new compounds have valuable pharmacological
giske egenskaper. Således blokkerer de kardial p-reseptorer som er vist på bestemmelsen av antagonisme av tachykardia etter en intravenøs injeksjon av 0,5 yg/kg av d/l-isopro- gic properties. Thus, they block cardiac β-receptors as shown in the determination of antagonism of tachycardia after an intravenous injection of 0.5 µg/kg of d/l-isopro-
terenolsulfat på en anestesert katt ved en intravenøs dose på 0,002 til 2 mg/kg. Således blokkerer de vasku^ar fJ-resep- terenol sulfate on an anesthetized cat at an intravenous dose of 0.002 to 2 mg/kg. Thus, they block vascular fJ-resep-
torer som er vist på bestemmelsen av antagonismen av vasi- tors shown on the determination of the antagonism of the vasi-
dilateringen etter en intravenøs injeksjon av. 0,5 yg/kg av d/l-isopropterenolsulfat på en anestetisert katt ved en intravenøs dose på 3 mg/kg eller mer. De er således hjerte- the dilatation after an intravenous injection of. 0.5 ug/kg of d/l-isopropterenol sulfate on an anesthetized cat at an intravenous dose of 3 mg/kg or more. They are thus heart-
selektive. selective.
De nye forbindelser kan benyttes som kardioselek- The new compounds can be used as cardioselective
tive antagonister av adrenergikk (3-reseptorstimulatorer, tive antagonists of adrenergic (3-receptor stimulators,
fieks. ved behandling av eksogent eller endogent bevirket ary^me og angina pectoris. fieks. in the treatment of exogenously or endogenously caused arrhythmia and angina pectoris.
De nye forbindelser fremstilles etter i og for The new connections are made according to i and for
seg kjente fremgangsmåter. known procedures.
Således blir en forbindelse med formel II Thus a compound of formula II becomes
hvori R har ovennevnte betydning og X betyr en hydroksy- in which R has the above meaning and X means a hydroxy-
gruppe og Z er en reaktiv, forestret hydroksygruppe eller X^" og Z danner sammen en epoksygruppe, omsatt med et amin group and Z is a reactive, esterified hydroxy group or X^" and Z together form an epoxy group, reacted with an amine
med formel III with formula III
En reaktiv forestret hydroksygruppe er spesielt en hydroksygruppe forestret med en sterk, uorganisk eller organisk syre, fortrinnsvis en hydrohalogensyre som hydroklorsyre, hydrobromsyre eller hydrojodsyre, videre svovelsyre eller en sterkt organisk sulfonsyre som en sterk aromatisk sulfonsyre, f.eks. benzensulfonsyre, 4-brom-benzensulfonsyre eller 4-toluensulfonsyre. Z er fortrinnsvis klor, brom eller jod. A reactive esterified hydroxy group is in particular a hydroxy group esterified with a strong, inorganic or organic acid, preferably a hydrohalic acid such as hydrochloric acid, hydrobromic acid or hydroiodic acid, further sulfuric acid or a strong organic sulphonic acid such as a strong aromatic sulphonic acid, e.g. benzenesulfonic acid, 4-bromobenzenesulfonic acid or 4-toluenesulfonic acid. Z is preferably chlorine, bromine or iodine.
Denne reaksjon utføres på vanlig måte. Ved This reaction is carried out in the usual way. By
bruk av en reaktiv ester som utgangsmateriale finner frem-stillingen sted fortrinnsvis i nærvær av et basisk kondensasjonsmiddel og/eller med et overskudd av et amin. use of a reactive ester as starting material, the preparation preferably takes place in the presence of a basic condensation agent and/or with an excess of an amine.
Egnede basiske kondenseringsmidler er f.eks. alkalimetall-hydroksyder som natrium eller kaliumhydroksyd, alkali-metallkarbonater som kaliumkarbonat og alkalinvetallalko-holater som natriummetylat, kaliumetylat og kalium-tert. butylat. Suitable basic condensing agents are e.g. alkali metal hydroxides such as sodium or potassium hydroxide, alkali metal carbonates such as potassium carbonate and alkali metal alcohols such as sodium methylate, potassium ethylate and potassium tert. butylate.
Videre omsettes en forbindelse med formel IV Furthermore, a compound of formula IV is reacted
hyori R har ovennevnte betydning, med en forbindelse med formel V hyori R has the above meaning, with a compound of formula V
hvori Z har ovennevnte betydning. wherein Z has the above meaning.
Omsetningen utføres på vanlig måte, fortrinnsvis i nærvær av et basisk kondensasjonsmiddel og/eller et overskudd a<y> et amin. Egnede basiske kondensasjonsmidler er f.eks. alkalialkoholater, fortrinnsivs natrium- eller kaliumalkoholat, eller også alkalikarbonater som natrium-eller kaliumkarbonat. The reaction is carried out in the usual way, preferably in the presence of a basic condensing agent and/or an excess of an amine. Suitable basic condensation agents are e.g. alkali alcoholates, preferably sodium or potassium alcoholate, or also alkali carbonates such as sodium or potassium carbonate.
Videre omsettes en forbindelse med formel VI Furthermore, a compound of formula VI is reacted
hvori R 1 har ovennevnte betydning og M er hydrogen eller et alkalimetall med en forbindelse med formel VII wherein R 1 has the above meaning and M is hydrogen or an alkali metal with a compound of formula VII
hvori Z og X"*" har ovennevnte betydning. wherein Z and X"*" have the above meaning.
Reaksjonen utføres på. vanlig måte. I de tilfeller hvor det benyttes reaktive estere som utgarigsmate-riale, kan forbindelsen med formel VI hensiktsmessig benyttes i form av metallfeholatet som alkalifenolat, fortrinnsvis natriumfenolat eller arbeides i nærvær av et syrebindende middel, fortrinnsvis et kondenseringsmiddel som kan danne et salt med forbindelsen med formel VI som et alkalimetallalkoholat. The reaction is carried out on usual way. In those cases where reactive esters are used as excipients, the compound of formula VI can conveniently be used in the form of the metal pheolate as alkali phenolate, preferably sodium phenolate, or worked in the presence of an acid-binding agent, preferably a condensing agent which can form a salt with the compound of formula VI as an alkali metal alcoholate.
Videre kan i en forbindelse med formel I som dessuten inneholder en avspaltbar rest ved nitrogen og/eller hydroksygruppen, hvori R"<1>" har den angitte betydning, nevnte avspaltbare rest avspaltes. Furthermore, in a compound of formula I which also contains a cleavable residue at nitrogen and/or the hydroxy group, in which R"<1>" has the stated meaning, said cleavable residue can be cleaved off.
Slike avspaltbare rester er spesielt de som er avspaltbare ved solvolyse, reduksjon, pyrolyse eller fer-mentering . Such decomposable residues are especially those which can be decomposed by solvolysis, reduction, pyrolysis or fermentation.
Rester som er avspaltbare ved solvolyse er fortrinnsvis rester som er avspaltbare ved hydrolyse eller ammonolyse. Residues that can be cleaved by solvolysis are preferably residues that can be cleaved by hydrolysis or ammonolysis.
Avspaltbare rester ved hjelp av hydrolyse er f.eks. acylrest som når den er tilstede, er funksjonelt varierte karboksygrupper, f.eks. oksykarbonylrester som alkoksykarbonylrester, f.eks. tert.butoksykarbonylrest eller etoksykarbonylrest, aralkoksykarbonylrest som fenyl-laverealkoksykarbonylrester, f.eks. en karbobenzyloksy-rest, halogenkarbonylrest, f.eks. en klorkarbonylrest, videre arylsulfonylrest som toluensulfonyl eller bromben-zensulfonylrester og eventuelt som halogenert, som fluorert laverealkanoyl rest som formyl-, acetyl- eller trifluoracetylrest eller en benzylrest eller cyanogrupper eller silylrester, som trimetylsilylrest. Cleavable residues by means of hydrolysis are e.g. acyl residue which, when present, are functionally varied carboxy groups, e.g. oxycarbonyl radicals such as alkoxycarbonyl radicals, e.g. tert.butoxycarbonyl residue or ethoxycarbonyl residue, aralkyloxycarbonyl residue such as phenyl-lower oxycarbonyl residue, e.g. a carbobenzyloxy radical, halocarbonyl radical, e.g. a chlorocarbonyl residue, further arylsulfonyl residue such as toluenesulfonyl or bromobenzenesulfonyl residues and optionally as halogenated, as fluorinated lower alkanoyl residue such as formyl, acetyl or trifluoroacetyl residue or a benzyl residue or cyano groups or silyl residues, such as trimethylsilyl residue.
Av ovennevnte rester som er tilstede ved hydroksygruppene, hvilke rester er avspaltbare ved hydrolyse er fortrinnsvis oksykarbonylrester og laverealkanoyl-rester eller benzoylrester. Of the above-mentioned residues which are present at the hydroxy groups, which residues are cleavable by hydrolysis are preferably oxycarbonyl residues and lower alkanoyl residues or benzoyl residues.
Ved siden av ovennevnte også dobbeltbundne rester som er avspaltbare ved aminogruppen ved hydrolyse benyttes f.eks. alkylidenrest eller en fosforyliden gruppe som en trifenylfosforylidengruppe, idet nitrogenatomet da får en positiv ladning. In addition to the above, double-bonded residues which can be split off at the amino group by hydrolysis are used, e.g. alkylidene residue or a phosphorylidene group such as a triphenylphosphorylidene group, the nitrogen atom then receiving a positive charge.
Avspaltbare rester ved hydroksygruppen og aminogruppen ved hjelp av hydrolyse er videre divalente rester som i enkelte tilfeller er substituert med metylen. Som substituenter på metylenrestene kan det benyttes enhver organisk rest, idet det ikke spiller noen rolle under hydrolysen, hvilke forbindelser som er substituent til metylenresten. Som metylensubstituenter f.eks. alifatiske eller aromatiske rester som alkyl som nevnt ovenfor, aryl f.eks. fenyl eller pyridyl kan benyttes. Hydrolysen kan utføres på vanlig måte, hensiktsmessighet basisk eller fortrinnsvis i et surt medium. Cleavable residues at the hydroxy group and the amino group by means of hydrolysis are further divalent residues which in some cases are substituted with methylene. As substituents on the methylene residues, any organic residue can be used, as it does not play any role during the hydrolysis, which compounds are substituents for the methylene residue. As methylene substituents e.g. aliphatic or aromatic residues such as alkyl as mentioned above, aryl e.g. phenyl or pyridyl can be used. The hydrolysis can be carried out in the usual way, where appropriate basic or preferably in an acidic medium.
Videre kan en Schiff<1>sk base med formel X eller XI Furthermore, a Schiff<1>sk base of formula X or XI
eller en cyklisk tautomer tilsvarende formel XI med formel XII reduseres, idet <R>1 har ovennevnte betydning, og R"^~ er en gruppe med formel IX or a cyclic tautomer corresponding to formula XI with formula XII is reduced, wherein <R>1 has the above meaning, and R"^~ is a group of formula IX
131 13 131 13
og R H er den samme som R og idet forbindelsen med formel XI and R H is the same as R and as the compound of formula XI
13 13
er den samme som R og idet forbindelsen med formel XI is the same as R and as the compound of formula XI
og XII eksisterer også sammen. Reduksjonen utføres på vanlig måte, f.eks. ved å benytte et di-lettmetallhydrid som natriumborhydrid, litiumaluminiumhydrid, idet det benyttes et hydrid som Boran med maursyre eller ved hjelp av en katalytisk hydrogenering som med hydrogen i nærvær av Raney-nikkel. Ved reduksjonen må det påsees at andre grupper ikke påvirkes. and XII also coexist. The reduction is carried out in the usual way, e.g. by using a di-lite metal hydride such as sodium borohydride, lithium aluminum hydride, using a hydride such as borane with formic acid or by means of a catalytic hydrogenation such as with hydrogen in the presence of Raney nickel. During the reduction, it must be ensured that other groups are not affected.
Videre kan oksogruppen i forbindelsen med formel XIII hvori R har ovennevnte betydning, reduseres til hydroksygruppe. Denne reduksjon utføres på vanlig måte, spesielt idet det benyttes et di-lettmetallhydrid som nevnt ovenfor, eller ifølge "Meerwein-Pendorf-Verley"-metoden eller en modifikasjon herav, hensiktsmessig under anvendelse av en alkanol som reaksjonskomponent og som oppløsningsmiddel, som isopropanol og idet det benyttes et metallalkanolat som metallisopropanolat f.eks. aluminiumisopropanolat. Furthermore, the oxo group in the compound of formula XIII in which R has the above meaning can be reduced to a hydroxy group. This reduction is carried out in the usual way, in particular using a di-light metal hydride as mentioned above, or according to the "Meerwein-Pendorf-Verley" method or a modification thereof, suitably using an alkanol as reaction component and as solvent, such as isopropanol and in that a metal alkanolate such as metal isopropanolate is used, e.g. aluminum isopropanolate.
Videre en forbindelse med formel XIV Furthermore, a compound of formula XIV
hvori X 2 er en rest som er istand til å overføres til en rest R 1 med ovennevnte betydning, overføres X 2 til R 1. wherein X 2 is a residue capable of being transferred to a residue R 1 with the above meaning, X 2 is transferred to R 1.
2 2
En rest X som er istand til å overføres til A remainder X capable of being transferred to
R 1 er f.eks. en rest X 2 overførbar til en alkoksyalkylrest R^ som en Z"*"-al kyl rest. En forbindelse XIV som har en R 1 is e.g. a residue X 2 transferable to an alkoxyalkyl residue R 1 as a Z"*"-alkyl residue. A compound XIV having a
slik rest Z 1 alkyl som X 2 kan omsettes på vanlig måte med such residue Z 1 alkyl with which X 2 can be reacted in the usual way
2 12 2 12
en forbindelse alkyl-Z , idet en av Z og Z er en hydroksygruppe og den annen er Z med ovennevnte betydning. a compound alkyl-Z, one of Z and Z being a hydroxy group and the other being Z with the above meaning.
En forbindelse med formel XXVIII A compound of formula XXVIII
hvori R og Z har den ovenfor angitte betydning, omsettes med p-karbamoylfenol. En forbindelse med formel VI" in which R and Z have the meaning indicated above, is reacted with p-carbamoylphenol. A compound of formula VI"
1 ^ 1 ^
hvori R har ovennevnte betydning omsettes med en forbindelse med formel XXXVIII wherein R has the above meaning is reacted with a compound of formula XXXVIII
13 13
CH0 - N - R CH0 - N - R
I 2 In 2
HO - CH - CH2HO-CH-CH2
13 13
hvor R har den ovennevnte betydning. where R has the above meaning.
Denne reaksjon utføres på vanlig måte. Således utføres reaksjonen under alkaliske betingelser i et egnet opp-løsningsmiddel som benzylalkohol ved å koke reaksjonsblandingen i noen timer. Derved overføres fenolet primært til metallfenolatet som alkalimetallfenolat før det settes til acetidinol med formel XXX. This reaction is carried out in the usual way. Thus, the reaction is carried out under alkaline conditions in a suitable solvent such as benzyl alcohol by boiling the reaction mixture for a few hours. Thereby, the phenol is primarily transferred to the metal phenolate as alkali metal phenolate before it is added to acetidinol of formula XXX.
Videre i en forbindelse med. formel.XL Furthermore, in connection with. formula.XL
hvori R"*" har ovennevnte betydning og X"^ er en rest som er overførbar til hydrogen, overføres X ® til hydrogen. wherein R"*" has the above meaning and X"^ is a residue transferable to hydrogen, X ® is transferred to hydrogen.
En rest X som er istand til å overføres til hydrogen er X<10> som er benzyl eller alkanoyl som hydroly-seres. A residue X which is capable of being transferred to hydrogen is X<10> which is benzyl or alkanoyl which is hydrolysed.
Ovennevnte reaksjoner kan eventuelt utføres samtidig eller etter hverandre.i en hvilken som helst rekkefølge. The above-mentioned reactions can optionally be carried out simultaneously or one after the other in any order.
Ovennevnte reaksjoner utføres på i og for seg kjent måte i nærvær eller i fravær av fortynningsmidler, kondenseringsmidler og/eller katalytiske stoffer ved lav-værelses- eller forhøyet temperatur, eventuelt i et lukket kar. The above-mentioned reactions are carried out in a manner known per se in the presence or in the absence of diluents, condensing agents and/or catalytic substances at low room or elevated temperature, possibly in a closed vessel.
Avhengig av fremgangsmåtebetingelsene og ut-gangsmaterialet oppnås sluttproduktet enten i fri form eller i form av et syreaddisjonssalt som omfattes av opp-finnelsens ramme. Depending on the process conditions and the starting material, the end product is obtained either in free form or in the form of an acid addition salt which is covered by the scope of the invention.
Således kan f.eks. de basiske, nøytrale eller blandede salter oppnås så vel som hemiamino-, sesqui-eller polyhydrater. Syreaddisjonssaltene av de nye forbindelser kan på i og for seg kjent måte overføres til frie forbindelser, idet det f.eks. benyttes basiske stoffer som alkali eller ioneutvekslere. På den annen side kan Thus, e.g. the basic, neutral or mixed salts are obtained as well as hemiamino-, sesqui- or polyhydrates. The acid addition salts of the new compounds can be transferred to free compounds in a manner known per se, as e.g. basic substances such as alkali or ion exchangers are used. On the other hand, it can
de dannede baser danne salter med organiske eller uorgaj niske syrer. Ved fremstilling av syreaddisjonssalter benyttes fortrinnsvis slike syrer som danner egnede terapeutisk godtagbare salter. Slike syrer er f.eks. hydro-halogensyrer, svovelsyre, fosforsyre, salpetersyre, per-klorsyre, alifatisk, alicyklisk, aromatisk eller hetero-cyklisk karboksy- eller sulfonsyre som maursyre, eddiksyre, propionsyre, ravsyre, glykolsyre, melkesyre, eplesyre, vinsyre, sitronsyre, ascorbinsyre, maleinsyre, hydroksy-maleinsyre eller pyrodruesyre, fenyleddiksyre, benzosyre, p-aminobenzosyre, antranilinsyre, p-hydroksybenzosyre, salicylsyre, eller p-aminosalicylsyre, embonsyre, metan-sulfonsyre, etansulfonsyre, hydroksyetansulfonsyre, etylen-sulfonsyre, halogenbenzensulfonsyre, toluensulfonsyre, naftylsulfonsyre eller sulfanylsyre, metionin, tryptofan, lysin eller arginin. the bases formed form salts with organic or inorganic acids. In the preparation of acid addition salts, such acids are preferably used which form suitable therapeutically acceptable salts. Such acids are e.g. hydrohalic acids, sulfuric acid, phosphoric acid, nitric acid, perchloric acid, aliphatic, alicyclic, aromatic or heterocyclic carboxylic or sulfonic acids such as formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic or pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, anthranilic acid, p-hydroxybenzoic acid, salicylic acid, or p-aminosalicylic acid, embonic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, halobenzenesulfonic acid, toluenesulfonic acid, naphthylsulfonic acid or sulfanyl acid, methionine , tryptophan, lysine or arginine.
Disse eller andre salter av de nye forbindelser som f.eks. pikrater kan tjene som rensestoffer for de frie baser som dannes som når de frie baser overføres til salter, disse adskilles fra basene og frigjøres fra saltene igjen. Ifølge de nære forhold mellom de nye forbindelser i fri form og i form av deres salter skal det forstås fra det ovennevnte og det følgende at, hvis mulig, innbefattes de tilsvarende salter i den fri forbindelse. These or other salts of the new compounds such as e.g. picrates can serve as cleaning substances for the free bases that are formed as when the free bases are transferred to salts, these are separated from the bases and released from the salts again. According to the close relationship between the new compounds in free form and in the form of their salts, it is to be understood from the above and the following that, if possible, the corresponding salts are included in the free compound.
Oppfinnelsen vedrører også en hvilken som helst utførelsesform av fremgangsmåten hvor man går ut fra en forbindelse oppnådd som mellomprodukt i hvilket som helst fremgangsmåtetrinn og det utføres i manglende fremgangsmåtetrinn eller fremgangsmåten avbrytes på et hvilket som helst trinn eller hvor man danner et utgangsmateriale under reaksjonsbetingelsene, eller hvor en reaksjonskomponent eventuelt er tilstede i form av saltet. The invention also relates to any embodiment of the process where one starts from a compound obtained as an intermediate in any process step and it is carried out in a missing process step or the process is interrupted at any step or where a starting material is formed under the reaction conditions, or where a reaction component is optionally present in the form of the salt.
Utgangsmaterialene er i og for seg kjente, men hvis de er nye, kan de dannes ifølge i og for seg kjente fremgangsmåter. The starting materials are known per se, but if they are new, they can be formed according to methods known per se.
Ved klinisk bruk administreres forbindelsene ifølge oppfinnelsen normalt oralt, rektalt eller ved injeksjon i form av farmasøytiske preparater som inneholder en aktiv komponent enten som fri base eller som et farma-søytisk tålbart ikke-toksisk syreaddisjonssalt, f.eks. In clinical use, the compounds according to the invention are normally administered orally, rectally or by injection in the form of pharmaceutical preparations containing an active component either as a free base or as a pharmaceutically acceptable non-toxic acid addition salt, e.g.
som hydrokloridlactatet, acetatet, sulfamatet eller lignende i kombinasjon med"en farmasøytisk tålbar bærer. Følgelig er omtalte av de nye forbindelser ifølge oppfinnelsen her referert til enten den fri aminbase eller syreaddisjonssaltene av den fri base, sel.v hvis forbindelsen er generelt og spesielt omtalt, forutsatt at innholdet hvor slike uttrykk benyttes f.eks. i eksemplene ikke til-svarer denne brede betydning. Bæreren kan være et fast, halvfast eller flytende fortynningsmiddel eller en kapsel. Disse farmasøytiske preparater er også gjenstand for oppfinnelsen. Vanligvis er mengden av aktivt stoff mellom 0,1 og 95 vekt% av preparatet, hensiktsmessig mellom 0,5 such as the hydrochloride lactate, the acetate, the sulfamate or the like in combination with a pharmaceutically acceptable carrier. Accordingly, the new compounds according to the invention mentioned here are referred to either the free amine base or the acid addition salts of the free base, even if the compound is generally and specifically mentioned , provided that the content where such expressions are used, for example in the examples, does not correspond to this broad meaning. The carrier can be a solid, semi-solid or liquid diluent or a capsule. These pharmaceutical preparations are also subject to the invention. Usually the amount of active substance between 0.1 and 95% by weight of the preparation, suitably between 0.5
og 20 vekt% i preparatet for injeksjon og mellom 2 0og 50 vekt% i preparatet for oral administrering. and 20% by weight in the preparation for injection and between 20 and 50% by weight in the preparation for oral administration.
Den daglige dose av det aktive stoff varierer og er avhengig av administreringstypen, men som generell regel ligger den mellom 100 til 400 mg/dag aktivt stoff ved peroral administrering og 5 til 20 mg/dag ved intrave-nøs administrering. The daily dose of the active substance varies and depends on the type of administration, but as a general rule it is between 100 to 400 mg/day of active substance for oral administration and 5 to 20 mg/day for intravenous administration.
Følgende'eksempler forklarer oppfinnelsen nærmere: The following examples explain the invention in more detail:
Eksempel 1 Example 1
2,60 g 1,27epoksy-3-[2-(N-hydroksyetyl-karba-moylmetoksy)fenoksy]-propan og 1,8 g 4-(2-aminoetoksy)benz-amid tilbakeløpskokes i 30 ml isopropanol i 3 timer. Reaksjonsblandingen inndampes i vakuum, hvorpå residuet opp-løses i aceton, det utfelles cyklamatet av 1-[2-(4-karba-moylfenoksy)etylamino]-3-[2-(N-hydroksyetylkarbamoylmetoksy)-fenoksy]propanol-2 med smp. 146-155°C. 2.60 g of 1,27-epoxy-3-[2-(N-hydroxyethyl-carbamoylmethoxy)phenoxy]-propane and 1.8 g of 4-(2-aminoethoxy)benzamide are refluxed in 30 ml of isopropanol for 3 hours. The reaction mixture is evaporated in vacuo, after which the residue is dissolved in acetone, the cyclamate of 1-[2-(4-carbamoylphenoxy)ethylamino]-3-[2-(N-hydroxyethylcarbamoylmethoxy)-phenoxy]propanol-2 is precipitated with m.p. . 146-155°C.
Eksempel 2 Example 2
2,75 g 1,2-epoksy-3-[2-(N-metoksyetylkarbamoyl-metoksy) f enoksy] propan og 1,8 g 4-(2-aminoetoksy)benzamid tilbakeløpskokes i 25 ml isopropanol i 1 1/2 time. Reaksjonsblandingen inndampes i vakuum, hvorpå residuet oppløses i aceton og det utfelles oksalatet av l-[2-(4-karbamoylfenoksy)etylamino]- 3-[2-(N-metoksyetylkarbamoyl-metoksy) f enoksy] propanol-2, med smp. 100-110°C. 2.75 g of 1,2-epoxy-3-[2-(N-methoxyethylcarbamoyl-methoxy)phenoxy]propane and 1.8 g of 4-(2-aminoethoxy)benzamide are refluxed in 25 ml of isopropanol for 1 1/2 hours . The reaction mixture is evaporated in vacuo, after which the residue is dissolved in acetone and the oxalate of l-[2-(4-carbamoylphenoxy)ethylamino]-3-[2-(N-methoxyethylcarbamoyl-methoxy)phenoxy]propanol-2 is precipitated, with m.p. 100-110°C.
Eksempel 3 (alternativ a: X<1>=0H, Z=C1) Example 3 (alternative a: X<1>=0H, Z=C1)
2,95 g l-klor-3-[2-(N-hydroksyetylkarbamoyl-metoksy) f enoksy] -propanol-2 og 1,8 g 4-(2-aminoetoksy)-benzamid tilbakeløpskokes i 25 ml isopropanol i 2 1/2 time. Reaksjonsblandingen inndampes i vakuum, hvoretter residuet oppløses i aceton og cyklamatet av l-[2-(4-karbamoylfenoksy) etylamino]-3-[2-(N-hydroksyetylkarbamoylmetoksy)fenoksy] - propanol-2 felles ut. Smp. 146-155°C. 2.95 g of 1-chloro-3-[2-(N-hydroxyethylcarbamoyl-methoxy)phenoxy]-propanol-2 and 1.8 g of 4-(2-aminoethoxy)-benzamide are refluxed in 25 ml of isopropanol in 2 1/ 2 hours. The reaction mixture is evaporated in vacuo, after which the residue is dissolved in acetone and the cyclamate of 1-[2-(4-carbamoylphenoxy)ethylamino]-3-[2-(N-hydroxyethylcarbamoylmethoxy)phenoxy]propanol-2 is precipitated. Temp. 146-155°C.
Eksempel 4 (variant b) Example 4 (variant b)
10 g 2-(N-hydroksyetylkarbamoylmetoksy)-fenyl-glycidyleter i 100 ml etanol mettes med gassformet ammoniakk og blandingen oppvarmes i et autoklav på kokende vannbad i 4 timer. Deretter fordampes oppløsningsmidlet og residuet oppløses i etylacetat og HCl-gass innføres. Derved ut-krystalliserer hydrokloridet, som frafiltreres og oppløses i 60 ml etanol, samt blandes med 15 g 2-(4-karbamylfenoksy)-etyljodid og 20 g I^COg. Blandingen oppvarmes i autoklav ved 120°C i 10 timer, hvoretter oppløsningsmidlet fordampes og residuet blandes med 100 ml 2N HCl og 100 ml eter. Vannfasen fraskilles og gjøres alkalisk med 2N NaOH og ekstraheres med etylacetat. Etylacetatfasen tørkes med K^CO^» hvoretter cyklamatet utfelles. Cyklamatet av 1-[2-(4-karbamyl-fenoksy)etylamino]-3-[2-(N-hydroksyetylkarbamoylmetoksy)-fenoksy]-propanol-2 smelter ved 146-155°C 10 g of 2-(N-hydroxyethylcarbamoylmethoxy)-phenyl glycidyl ether in 100 ml of ethanol is saturated with gaseous ammonia and the mixture is heated in an autoclave on a boiling water bath for 4 hours. The solvent is then evaporated and the residue is dissolved in ethyl acetate and HCl gas is introduced. Thereby the hydrochloride crystallizes out, which is filtered off and dissolved in 60 ml of ethanol, and mixed with 15 g of 2-(4-carbamylphenoxy)-ethyl iodide and 20 g of I^COg. The mixture is heated in an autoclave at 120°C for 10 hours, after which the solvent is evaporated and the residue is mixed with 100 ml of 2N HCl and 100 ml of ether. The water phase is separated and made alkaline with 2N NaOH and extracted with ethyl acetate. The ethyl acetate phase is dried with K^CO^» after which the cyclamate is precipitated. The cyclamate of 1-[2-(4-carbamyl-phenoxy)ethylamino]-3-[2-(N-hydroxyethylcarbamoylmethoxy)-phenoxy]-propanol-2 melts at 146-155°C
Eksempel 5 (variant c) Example 5 (variant c)
3,0 g Na oppløses i 100 ml etanol, hvoretter det tilsettes 25,1 g 2-(N-hydroksyetylkarbamoylmetoksy)-fenol og 19,0 g 1-[2-(4-karbamylfenoksy)etylamino]-3-klorpropanol-2. Blandingen oppvarmes i autoklav på kokende vannbad i 15 timer. Deretter filtreres reaksjonsblandingen og filtratet inndampes til tørrhet. Residuet blandes med 2N HCl og ekstraheres med eter, hvoretter vannfasen gjøres alkalisk med 2N NåOH og ekstraheres med eter. Etter tørking av eterfasen med K^ ZO^ utfelles cyklamatet. Således fåes 1- [2-(4-karbamylfenoksy)etylamino]-3-(2-(N-hydroksyetyl-karbamoylmetoksy ) -f enoksy) -propanol 2. cyklamat. Smp. 146-155°C. 3.0 g of Na are dissolved in 100 ml of ethanol, after which 25.1 g of 2-(N-hydroxyethylcarbamoylmethoxy)-phenol and 19.0 g of 1-[2-(4-carbamylphenoxy)ethylamino]-3-chloropropanol-2 are added . The mixture is heated in an autoclave on a boiling water bath for 15 hours. The reaction mixture is then filtered and the filtrate is evaporated to dryness. The residue is mixed with 2N HCl and extracted with ether, after which the aqueous phase is made alkaline with 2N NaOH and extracted with ether. After drying the ether phase with K^ ZO^ the cyclamate is precipitated. Thus 1-[2-(4-carbamylphenoxy)ethylamino]-3-(2-(N-hydroxyethyl-carbamoylmethoxy)-phenoxy)-propanol 2. cyclamate is obtained. Temp. 146-155°C.
Eksempel 6 (variant d) Example 6 (variant d)
I henhold til foregående eksempel fremstilles N-benzyl-1-[2-(4-karbamylfenoksy)etylamino]-3-(2-(N-hydrok-syetylkarbamoylmetoksy) f enoksy) -propanol-2- cyklamat fra 2- (N-hydroksyetylkarbamoylmetoksy)-fenol og N-benzyl-1-[2-(4-karbamyl)etylamino]-3-klor-propanol-2. lO<q>g av forbindelsen oppløses i 100 ml etanol, blandes med 0,5 g Pd/C According to the preceding example, N-benzyl-1-[2-(4-carbamylphenoxy)ethylamino]-3-(2-(N-hydroxyethylcarbamoylmethoxy)phenoxy)-propanol-2-cyclamate is prepared from 2-(N- hydroxyethylcarbamoylmethoxy)-phenol and N-benzyl-1-[2-(4-carbamyl)ethylamino]-3-chloro-propanol-2. 10<q>g of the compound is dissolved in 100 ml of ethanol, mixed with 0.5 g of Pd/C
og hydrogeneres til oppgak av beregnet hydrogenmengde. and hydrogenated to meet the calculated hydrogen quantity.
Etter filtrering inndampes til tørrhet og residuet omkrystal-liseres fra acetonitril. 1-[2-(4-karbamylfenoksy)etylamino]-3- (2-(N-hydroksyetylkarbamoylmetoksy)-fenoksy)-propanol-2 . cyklamat som fåes, smelter ved 146-1550C. After filtration, the mixture is evaporated to dryness and the residue is recrystallized from acetonitrile. 1-[2-(4-Carbamylphenoxy)ethylamino]-3-(2-(N-Hydroxyethylcarbamoylmethoxy)-phenoxy)-propanol-2. cyclamate that is obtained melts at 146-1550C.
Eksempel 7 (metode e) Example 7 (method e)
10 g l-amino-3-(2-N-hydroksyetylkarbamoyl-metoksy)-fenoksy)-propanol-2 (oppnådd i henhold til variant b ovenfor) oppløses i 80 ml metanol og kondenseres med 10 g 2-(4-karba-mylf enoksy) etan-l-al for dannelse av 1-[2-(4-karbamoyl-fen-oksy ]-propanol-2 (formel XI). Metanoloppløsningen innehold-ende iminoforbindelsene avkjøles i isbad og tilsettes porsjonsvis 10 g natriumborhydrid. Temperaturen øket deretter til værelsestemperatur og etter 1 time ble det tilsatt 200 ml H20 og blandingen ekstrahert med eter. Eterfasen ble tørket over K2C03 og stoffet ble overført til cyklamat-salt. Cyklametet av 1-[2-(4-karbamyl-fenoksy)etyl-amino ]-3-(2-(N-hydroksyetyl-karbamoylmetoksy)-fenoksy)-propanol-2 smelter ved 14 6-155°C. 10 g of 1-amino-3-(2-N-hydroxyethylcarbamoyl-methoxy)-phenoxy)-propanol-2 (obtained according to variant b above) are dissolved in 80 ml of methanol and condensed with 10 g of 2-(4-carba- mylf enoxy) ethan-l-al to form 1-[2-(4-carbamoyl-phen-oxy]-propanol-2 (formula XI). The methanol solution containing the imino compounds is cooled in an ice bath and 10 g of sodium borohydride is added in portions. The temperature then raised to room temperature and after 1 hour 200 ml H 2 O was added and the mixture extracted with ether. The ether phase was dried over K 2 CO 3 and the material was converted to the cyclamate salt. The cyclamate of 1-[2-(4-carbamyl-phenoxy)ethyl- amino ]-3-(2-(N-hydroxyethyl-carbamoylmethoxy)-phenoxy)-propanol-2 melts at 14 6-155°C.
Eksempel £ (metode f) Example £ (method f)
0,1 mol 1-[2-(4-karbamoylfenoksy)etylamino]-3-[2-(N-hydroksyetylkarbamoylmetoksy)-fenoksy]propan-2-al oppløses i 75 ml metanol og avkjøles på isbad. Deretter tilsettes 0,1 mol NaBH4 porsjonsvis. Temperaturen økes deretter til værelsetemperatur og etter en time ble det tilsatt 150 ml H20 og blandingen ekstrahert med eter. Eterfasen ble tørket over K2C03 og stoffet overført til cyklamatsaltet. Cyklamatet av 1-[2-(4-karbamoylfenoksy)-etylamino]-3-[2-(N-hydroksyetyl)karbamoylmetoksyfenoksy]-propanol-2 smelter ved 146-155°C. 0.1 mol of 1-[2-(4-carbamoylphenoxy)ethylamino]-3-[2-(N-hydroxyethylcarbamoylmethoxy)-phenoxy]propan-2-al is dissolved in 75 ml of methanol and cooled in an ice bath. 0.1 mol of NaBH4 is then added in portions. The temperature is then raised to room temperature and after one hour 150 ml H 2 O was added and the mixture extracted with ether. The ether phase was dried over K 2 CO 3 and the material transferred to the cyclamate salt. The cyclamate of 1-[2-(4-carbamoylphenoxy)-ethylamino]-3-[2-(N-hydroxyethyl)carbamoylmethoxyphenoxy]-propanol-2 melts at 146-155°C.
Eksempel 9 (metode g) Example 9 (method g)
0,1 mol l-[2-(4-karbamoylfenoksyd)etylamino]-3-[2-klorkarbonyl-metoksyfenoksy]-propanol-2 og 0,15 mol aminoetanol oppløses i 5 0ml etanol og tilsettes 20 g K2C03' Blandingen oppvarmes i autoklav ved 120°C i 8 timer, hvoretter oppløsningsmidlet avdampes. Forøvrig opparbei-des produktet i henhold til Eks.14 ovenfor. Smp. 146-155°C (cyklamat). 0.1 mol of 1-[2-(4-carbamoylphenoxide)ethylamino]-3-[2-chlorocarbonyl-methoxyphenoxy]-propanol-2 and 0.15 mol of aminoethanol are dissolved in 50 ml of ethanol and 20 g of K2C03 are added. The mixture is heated in autoclave at 120°C for 8 hours, after which the solvent is evaporated. Otherwise, the product is processed according to Ex. 14 above. Temp. 146-155°C (cyclamate).
Eksempel 10 (metode h) Example 10 (method h)
0,1 mol 1-(2-(N-hydroksyetylkarbamoylmetoksy)-fenoksy)-3-(2-brometylamino)-propanol-2, 0,1 mol 4-karbamoylfenol og I^CO^ i etanol tilbakeløpskokes i 2 timer. Reaksjonsblandingen filtreres og filtratet inndampes. Residuet blandes med 100 ml 2N HCl og 100 ml eter. Vannfasen fraskylles og gjøres alkalisk med 2N NaOH, samt ekstraheres med etylacetat. Etylacetatfasen tørkes over I^CO^, hvoretter cyklamatet utfelles. 1-[2-(4-karbamylfenoksy)-etyl-amino] -3-(2-N-hydroksyetylkarbamoylmetoksy)-fenoksy)-propanol-2. Cyklamat smelter ved 146-155°C. 0.1 mol of 1-(2-(N-hydroxyethylcarbamoylmethoxy)-phenoxy)-3-(2-bromomethylamino)-propanol-2, 0.1 mol of 4-carbamoylphenol and I^CO^ in ethanol are refluxed for 2 hours. The reaction mixture is filtered and the filtrate is evaporated. The residue is mixed with 100 ml of 2N HCl and 100 ml of ether. The water phase is rinsed off and made alkaline with 2N NaOH, and extracted with ethyl acetate. The ethyl acetate phase is dried over I^CO^, after which the cyclamate is precipitated. 1-[2-(4-Carbamylphenoxy)-ethyl-amino]-3-(2-N-hydroxyethylcarbamoylmethoxy)-phenoxy)-propanol-2. Cyclamate melts at 146-155°C.
Eksempel H (metode i) Example H (method i)
0,2 mol 2-(N-hydroksyetylkarbamoylmetoksy)- 0.2 mol 2-(N-hydroxyethylcarbamoylmethoxy)-
fenol blandes med 0,1 mol 1-[2-(4-karbamylfenoksy)-etyl]-3-acetidinol, 0,5 mol benzylalkohol samt 0,005 mol KOH. Blandingen oppvarmes under tilbakeløp og omrøring i 6 timer og 140°C i autoklav og avkjøles og ekstraheres med 2N HCl. Vannfasen gjøres alkalisk og ekstraheres med etylacetat. Etter tørking over K2C03 utfelles cyklamatet. l-[2-(4-karbamylfenoksy)-etylamino]-3-]2-(N-hydroksyetyl)karbamyl-metoksy-fenoksy]-propanol-2. Cyklamatet smelter' ved 146-155°C. phenol is mixed with 0.1 mol 1-[2-(4-carbamylphenoxy)-ethyl]-3-acetidinol, 0.5 mol benzyl alcohol and 0.005 mol KOH. The mixture is heated under reflux and stirring for 6 hours and 140°C in an autoclave and cooled and extracted with 2N HCl. The water phase is made alkaline and extracted with ethyl acetate. After drying over K2C03, the cyclamate precipitates. 1-[2-(4-carbamylphenoxy)-ethylamino]-3-]2-(N-hydroxyethyl)carbamyl-methoxy-phenoxy]-propanol-2. The cyclamate melts at 146-155°C.
Biologiske virkninger Biological effects
De p-reseptorblokkerende stoffer ifølge oppfinnelsen ble undersøkt med hensyn til deres biologiske egenskaper. Alle forbindelser ble derved undersøkt på anestesert katt (hannkatt og hunnkatt som veide 2,5-3,5 kg), forbehandlet med reserpin ( 5mg/kg legemsvekt administrert intramuskulært) omtrent 16 timer før eksperimentene. The β-receptor blocking substances according to the invention were examined with regard to their biological properties. All compounds were therefore examined on anesthetized cats (male and female cats weighing 2.5-3.5 kg), pre-treated with reserpine (5 mg/kg body weight administered intramuscularly) approximately 16 hours before the experiments.
Dyrene ble forbehandlet med reserpin for å eliminere den endogene sympatetiske kontroll av hjertevirksomhet og vaskulær bløtmuskelaktiviteten. Kattene ble anestesert med pentobarbital (30 mg/kg legemsvekt administrert i.p.) og kunstig åndedrett ved værelsesluft. En bilateral vagotomi ble performert i nakken. Blodtrykk ble oppnådd fra en kannulert karotidarterie og hjertegraden ble registrert fra et kardiotachometer, utløst av elektrokardio- The animals were pretreated with reserpine to eliminate the endogenous sympathetic control of cardiac activity and vascular smooth muscle activity. The cats were anesthetized with pentobarbital (30 mg/kg body weight administered i.p.) and artificially ventilated with room air. A bilateral vagotomy was performed in the neck. Blood pressure was obtained from a cannulated carotid artery and heart rate was recorded from a cardiotachometer, triggered by electrocardio-
gram (ECG). Intrinsikbeta-mimetisk aktivitet på hjertet fremkom som øket hjerteaktivitet etter preparatadministre-ring. Prøveforbindelsene ble gitt intravenøst i logarit- grams (ECG). Intrinsic beta-mimetic activity on the heart appeared as increased cardiac activity after preparation administration. The test compounds were administered intravenously in logarithmic
misk økende doser. De oppnådde verdier ble avtegnet på dosisavhengige kurver, hvorfra affinitetsverdier (ED^q) misc increasing doses. The obtained values were plotted on dose-dependent curves, from which affinity values (ED^q)
ble bestemt. Ved slutten av hvert eksperiment ble høye doser av isoprenalin gitt for å oppnå maksimal hjerte-aktivitetrespons. was determined. At the end of each experiment, high doses of isoprenaline were given to achieve a maximal cardiac activity response.
Forbindelsene ble også undersøkt på bevisste hunder. Beagle-hunder ble trenet til å ligge stille og The compounds were also examined in conscious dogs. Beagle dogs were trained to lie still and
til å løftes til en oppreist stilling ved å plassere for-benene på et bort i 2 minutter. Arterielt blodtrykk ble registrert via en blodtrykksmåler forbundet til hunden to be raised to an upright position by placing the forelegs on a away for 2 minutes. Arterial blood pressure was recorded via a blood pressure monitor connected to the dog
ved hjertenivå. Hjerteaktiviteten ble målt av ECG. Alle hunder ble forbehandlet med metylscopolamin for å unngå at heart level. Heart activity was measured by ECG. All dogs were pretreated with methylscopolamine to avoid
vågal påvirkning. Opptegninger ble tatt før og 15 og 75 minutter etter administreringen av prøveforbindelsen, først i liggestilling i 2 minutter og deretter i oppreist stil- daring influence. Recordings were taken before and 15 and 75 minutes after the administration of the test compound, first in the supine position for 2 minutes and then in the upright position.
ling i 2 minutter. Prøveforbindelsene ble gitt i økende doser med 2 timer intervaller. ling for 2 minutes. The test compounds were given in increasing doses at 2 hour intervals.
Tabell 1 nedenfor viser affinitetsverdier og intrinsikbeta-mimetisk aktivitet i reserpiniserte katter og virkninger på blodtrykket i bevisste hunder av forbindelsene ifølge oppfinnelsen. Tilsvarende verdier for propanolol, (l-isopropylamino-3-(1-naftoksy)-propanol-2), practolol, (4-(2-hydroksy-3-isopropylaminopropoksy)acet-anilid), metoprolol, (l-isopropylamino-3-[4-(2-metoksy-etyl)fenoksy]-propanol-2), tolamolol, [4-(2-[2-hydroksy-3-o-tolyloksypropylamino]etoksy)-benzamid] og AH 5158 (5-[l-hydroksy-2]-(l-metyl-3-fenylpropyl)-amino[etyl]-salicyl- Table 1 below shows affinity values and intrinsic beta-mimetic activity in reserpinized cats and effects on blood pressure in conscious dogs of the compounds according to the invention. Corresponding values for propanolol, (l-isopropylamino-3-(1-naphthoxy)-propanol-2), practolol, (4-(2-hydroxy-3-isopropylaminopropoxy)acetanilide), metoprolol, (l-isopropylamino-3 -[4-(2-methoxy-ethyl)phenoxy]-propanol-2), tolamolol, [4-(2-[2-hydroxy-3-o-tolyloxypropylamino]ethoxy)-benzamide] and AH 5158 (5-[ l-hydroxy-2]-(l-methyl-3-phenylpropyl)-amino[ethyl]-salicyl-
amid) er gjengitt for sammenligning. amide) are reproduced for comparison.
Forsøkene viste at forbindelsene som er under-søkt er potente 3-reseptor-antagonister med eller uten intrinsik-p<->mimetik aktivitet. Forbindelsene nedsetter blodtrykket i bevisste hunder tydelig mer enn propanolol, practolol og metoproplol og i samme utstrekning som tolamolol. The experiments showed that the compounds investigated are potent 3-receptor antagonists with or without intrinsic β-mimetic activity. The compounds lower blood pressure in conscious dogs clearly more than propanolol, practolol and metoprolol and to the same extent as tolamolol.
De ortostatiske effekter av de nye forbindelser er ikke så uttalt som for AH 5158, dvs. blodtrykket går ikke markert ned fra liggende til oppreist stilling. The orthostatic effects of the new compounds are not as pronounced as for AH 5158, i.e. the blood pressure does not drop markedly from the lying down to the upright position.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE7413789A SE422052B (en) | 1974-11-01 | 1974-11-01 | PROCEDURE FOR PREPARING CERTAIN STATED 1-PHENOXY-2-HYDROXY-3-AMINOPHENYL PROPYL DERIVATIVES |
Publications (3)
Publication Number | Publication Date |
---|---|
NO752765L NO752765L (en) | 1976-05-04 |
NO144773B true NO144773B (en) | 1981-07-27 |
NO144773C NO144773C (en) | 1981-11-04 |
Family
ID=20322597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO752765A NO144773C (en) | 1974-11-01 | 1975-08-06 | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINES. |
Country Status (24)
Country | Link |
---|---|
JP (1) | JPS51131839A (en) |
AT (1) | AT344142B (en) |
AU (1) | AU498770B2 (en) |
BE (2) | BE835090A (en) |
CA (1) | CA1093095A (en) |
CH (3) | CH618417A5 (en) |
CS (1) | CS189726B2 (en) |
DD (1) | DD119207A5 (en) |
DE (1) | DE2531312A1 (en) |
DK (1) | DK444475A (en) |
FI (1) | FI752201A (en) |
FR (1) | FR2289172A1 (en) |
GB (1) | GB1524036A (en) |
HK (1) | HK36081A (en) |
HU (1) | HU172652B (en) |
IE (1) | IE41652B1 (en) |
LU (1) | LU73703A1 (en) |
MY (1) | MY8200085A (en) |
NL (1) | NL7509548A (en) |
NO (1) | NO144773C (en) |
NZ (1) | NZ178313A (en) |
SE (1) | SE422052B (en) |
SU (3) | SU906368A3 (en) |
ZA (2) | ZA754241B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4119718A (en) * | 1977-05-02 | 1978-10-10 | Merck & Co., Inc. | 3-Amino-2-oxy-propoxy-substituted isothiazoles |
SE7807408L (en) * | 1978-06-30 | 1979-12-31 | Haessle Ab | HEART ACTIVE ASSOCIATIONS |
DD150456A5 (en) * | 1979-03-01 | 1981-09-02 | Ciba Geigy Ag | PROCESS FOR THE PREPARATION OF DERIVATIVES OF 3-AMINO-1,2-PROPANDIOL |
DE3125870C2 (en) * | 1980-07-09 | 1994-09-15 | William John Louis | 3-aminopropoxyphenyl derivatives, their preparation and medicaments containing them |
US4410548A (en) * | 1980-07-09 | 1983-10-18 | Reckitt & Colman Products Limited | Propanolamine derivatives |
FR2508032A1 (en) * | 1981-06-17 | 1982-12-24 | Delalande Sa | 3-Amino-2-aryloxy-methyl-1-propanol derivs. - are used to treat cardiovascular troubles, esp. angina esp 3-tri:methoxy-cinnamoyl-piperazino- 2-1,4-benzodioxan-5-yl-oxy-methyl cpds. |
DE3151201A1 (en) * | 1981-12-23 | 1983-07-28 | Beiersdorf Ag, 2000 Hamburg | SUBSTITUTED PHENOXYALKANOLAMINE AND PHENOXYALKANOL-CYCLOALKYLAMINE, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS |
SE457505B (en) * | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | LAMINATED ORAL PHARMACEUTICAL COMPOSITION AND PROCEDURES FOR ITS PREPARATION |
DE3433616A1 (en) * | 1984-08-08 | 1986-02-20 | BBC Aktiengesellschaft Brown, Boveri & Cie., Baden, Aargau | PROTECTIVE DEVICE FOR AN ELECTRICAL NET |
JPS6341451A (en) * | 1986-08-06 | 1988-02-22 | Nippon Kayaku Co Ltd | Ether derivative and miticidal and insecticidal composition containing said derivative as active component |
US5321036A (en) * | 1993-02-10 | 1994-06-14 | Bristol-Myers Squibb Company | Thiazole and oxazole-based β3 adrenergic receptor agonists |
-
1974
- 1974-07-02 ZA ZA00754241A patent/ZA754241B/en unknown
- 1974-11-01 SE SE7413789A patent/SE422052B/en unknown
-
1975
- 1975-07-02 ZA ZA00754240A patent/ZA754240B/en unknown
- 1975-07-12 DE DE19752531312 patent/DE2531312A1/en not_active Ceased
- 1975-07-31 AT AT592975A patent/AT344142B/en not_active IP Right Cessation
- 1975-07-31 FI FI752201A patent/FI752201A/fi not_active Application Discontinuation
- 1975-08-04 AU AU83637/75A patent/AU498770B2/en not_active Expired
- 1975-08-06 NZ NZ178313A patent/NZ178313A/en unknown
- 1975-08-06 NO NO752765A patent/NO144773C/en unknown
- 1975-08-08 DD DD187775A patent/DD119207A5/xx unknown
- 1975-08-08 SU SU752163123A patent/SU906368A3/en active
- 1975-08-11 NL NL7509548A patent/NL7509548A/en not_active Application Discontinuation
- 1975-08-14 IE IE1809/75A patent/IE41652B1/en unknown
- 1975-09-09 GB GB37073/75A patent/GB1524036A/en not_active Expired
- 1975-09-16 CH CH1196775A patent/CH618417A5/en not_active IP Right Cessation
- 1975-10-02 DK DK444475A patent/DK444475A/en unknown
- 1975-10-21 FR FR7532204A patent/FR2289172A1/en active Granted
- 1975-10-30 CS CS757328A patent/CS189726B2/en unknown
- 1975-10-30 HU HU75HE694A patent/HU172652B/en unknown
- 1975-10-31 CA CA238,763A patent/CA1093095A/en not_active Expired
- 1975-10-31 BE BE161438A patent/BE835090A/en unknown
- 1975-10-31 BE BE161439A patent/BE835091A/en unknown
- 1975-10-31 JP JP50131345A patent/JPS51131839A/en active Pending
- 1975-10-31 LU LU73703A patent/LU73703A1/xx unknown
-
1976
- 1976-09-03 SU SU762393515A patent/SU637078A3/en active
- 1976-09-03 SU SU762393516A patent/SU625599A3/en active
-
1979
- 1979-08-28 CH CH780979A patent/CH622490A5/en not_active IP Right Cessation
- 1979-08-28 CH CH781079A patent/CH622491A5/en not_active IP Right Cessation
-
1981
- 1981-07-31 HK HK360/81A patent/HK36081A/en unknown
-
1982
- 1982-12-30 MY MY85/82A patent/MY8200085A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CH618417A5 (en) | 1980-07-31 |
DK444475A (en) | 1976-05-02 |
SU637078A3 (en) | 1978-12-05 |
NL7509548A (en) | 1976-05-04 |
NZ178313A (en) | 1978-06-02 |
CH622491A5 (en) | 1981-04-15 |
SU625599A3 (en) | 1978-09-25 |
NO144773C (en) | 1981-11-04 |
GB1524036A (en) | 1978-09-06 |
AU498770B2 (en) | 1979-03-22 |
MY8200085A (en) | 1982-12-31 |
ATA592975A (en) | 1977-11-15 |
JPS51131839A (en) | 1976-11-16 |
BE835091A (en) | 1976-04-30 |
DE2531312A1 (en) | 1976-05-06 |
IE41652L (en) | 1976-05-01 |
SU906368A3 (en) | 1982-02-15 |
FR2289172A1 (en) | 1976-05-28 |
CA1093095A (en) | 1981-01-06 |
DD119207A5 (en) | 1976-04-12 |
AT344142B (en) | 1978-07-10 |
AU8363775A (en) | 1977-02-10 |
CS189726B2 (en) | 1979-04-30 |
FR2289172B1 (en) | 1980-11-21 |
NO752765L (en) | 1976-05-04 |
SE7413789L (en) | 1976-05-03 |
FI752201A (en) | 1976-05-02 |
HU172652B (en) | 1977-11-28 |
HK36081A (en) | 1981-07-31 |
SE422052B (en) | 1982-02-15 |
LU73703A1 (en) | 1976-08-13 |
IE41652B1 (en) | 1980-02-27 |
ZA754240B (en) | 1976-06-30 |
CH622490A5 (en) | 1981-04-15 |
BE835090A (en) | 1976-04-30 |
ZA754241B (en) | 1976-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005265769B2 (en) | 5-substituted-2-phenylamino-benzamides as MEK inhibitors | |
EP0041491B1 (en) | New para-substituted 3-phenoxy-1-alkylamino-propanol-2-s having beta receptor blocking properties | |
JPH05148196A (en) | 4-(2-(2-hydroxy-2-phenyl-ethylamino)ethoxy)- phenylacetic acid, precursor thereof, prepara- tion thereof, and pharmaceutical composition containing same | |
EA011407B1 (en) | Hydrates and polymorphs of 4-[[(7r)-8cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-4-6-oxo-2-piperidinyl]amino]-3-methoxy-n-(1-methyl-4-piperidinyl) benzamide, methods for the production thereof, and use thereof as medicaments | |
US4288452A (en) | 1-Aryloxy-3-nitratoalkylamino-2-propanols and use as β-receptor blocker | |
NO144773B (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINES | |
FI63745C (en) | FRAMEWORK FOR THE FRAMEWORK OF THERAPEUTIC MEDICINAL PRODUCTS | |
EP0041492B1 (en) | New substituted 3-phenoxy-1-alkoxycarbonyl-alkylamino-propanol-2-s having beta receptor blocking properties | |
NO140628B (en) | ANALOGICAL PROCEDURE FOR THE PREPARATION OF NEW THERAPEUTICALLY EFFECTIVE AMINES | |
JPS5924971B2 (en) | New method for producing amines | |
US4542127A (en) | Antidiabetic salicylic acid derivatives | |
CS214700B2 (en) | Method of making the 9-aminoalcylfluorenes | |
DK150196B (en) | METHOD OF ANALOGUE FOR THE PREPARATION OF 0- (3-AMINO-2-HYDROXYPROPYL) AMIDOXIME DERIVATIVES OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF | |
US3317545A (en) | [2-(2, 6-dimethylpiperidino)ethyl]guanidines and intermediates | |
CS239948B2 (en) | Processing of substitute n-carboxamidealkylfenoxypropanolamine | |
NO145436B (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINES | |
NO141753B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF NEW PROPANOLAMINES WITH BETA-RECEPTOR BLOCKING AND ALFA-RECEPTOR BLOCK EFFECT | |
US3905990A (en) | Basically substituted benzimidazole derivatives | |
RU1836330C (en) | Method for obtaining polyhydroxy benzyloxypropanol amines | |
GB2074576A (en) | 1-(acylamino-aryloxy)-3-alkylamino-propan-2-ols processes for their preparation and pharmaceutical compositions containing them | |
US3317526A (en) | Omega-tertiaryamino butynol-1-phenylcycloalkane carboxylates | |
US4000313A (en) | 1-Isopropylamino-3[4'-(2-methoxy- or ethoxy-carbonylaminoethoxy)-phenoxy]propanol-2 and cardioselective antagonism use | |
JPS5865276A (en) | Antiarrhythmic phenetylpiperidine compound | |
GB2098599A (en) | N-(2,6-disubstituted phenyl)-alkanediamines | |
IE60779B1 (en) | "New n-(1h-indol-4-yl)benzamide derivatives and also their salts, their application by way of medicinal products and the compositions containing them" |